Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ) \/ ]0 [' K( X
1 \, z* f: X, b I6 N
& a9 G" r) `% o4 j ^, \Sub-category:
" Z" S }5 y5 m/ z: G+ G% H8 N* O/ _Molecular Targets
% {- b! Q6 y; J! N, v2 c2 [# d
* R" ?* f$ D% k+ {; l2 h! i) |$ J; u( y7 a
Category:
( o. K- r5 ~: D- bTumor Biology ; }& a! J0 c: d
" z' ] W& @- ~4 w, q$ {* v: f+ V( \/ q, W& [' L+ I# j
Meeting:3 Q7 i$ K1 v0 \# p* R( u
2011 ASCO Annual Meeting 0 u8 c* X9 ^& z* B$ N
- L W$ m' A, f3 j
- y) o( {/ K! o" USession Type and Session Title:+ c. a4 b* Q) ^% Y2 ?
Poster Discussion Session, Tumor Biology
) k }& R, h! t1 P8 O& E0 ?7 y" J$ ^9 e$ A% p7 |
4 K' L$ i: J/ p1 }" kAbstract No:) e( I/ X! x6 v$ U3 U
10517
4 w' t8 D! Q. J V5 |
/ J5 a( S0 w: r- c9 D& }7 k$ B- j
c1 \5 M& ?# C# QCitation:( \' ^) j+ g$ G+ X
J Clin Oncol 29: 2011 (suppl; abstr 10517)
6 \# B6 i* H! e% U8 N$ w4 O8 c
; G* a. q3 A5 e* ~4 `3 H4 u# g
$ i9 Y# C4 n( _$ ^Author(s):
, ]5 M. U" x5 T4 ZJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 7 D7 N; P5 b. ~& o
$ m# |! r+ d' t6 H) y! f& h5 X! [. w. U
8 C. b4 U3 y! Z" u
; l9 z- o, g2 @4 K7 ^& i$ HAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
5 Z* `, [& a/ i9 A% g) n M; z2 r' `+ _7 g4 C. I; O
Abstract Disclosures
" c; _ {% O _* `
5 x9 t" v: m+ g4 H/ |' ]- CAbstract:
; \3 a. o5 b& y5 s( b, D
8 L& `' c6 C, G& K. Z8 |# l6 V0 E. F9 ~5 K8 H
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
* U! G [2 W) f: @
4 t. i X! ]" |: V 3 O: C$ Z7 U6 P" ]2 o+ r
|
4 q' J7 u5 Y3 {1 `- L3 {- A8 i
显身卡
